$2.18
6.24% yesterday
Nasdaq, Oct 15, 10:00 pm CET
ISIN
US45254U1016
Symbol
IMRN

Immuron Limited Sponsored ADR Stock price

$2.18
+0.32 17.10% 1M
+0.45 25.90% 6M
+0.48 28.12% YTD
+0.31 16.47% 1Y
+0.13 6.24% 3Y
-5.57 71.90% 5Y
+2.04 1,451.28% 10Y
+1.93 771.20% 20Y
Nasdaq, Closing price Wed, Oct 15 2025
+0.13 6.24%
ISIN
US45254U1016
Symbol
IMRN
Industry

Key metrics

Basic
Market capitalization
$14.7m
Enterprise Value
$12.8m
Net debt
positive
Cash
$1.8m
Shares outstanding
234.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3.1 | 1.2
EV/Sales
2.7 | 0.4
EV/FCF
negative
P/B
2.8
Financial Health
Equity Ratio
79.7%
Return on Equity
-64.6%
ROCE
-65.6%
ROIC
-93.5%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$4.7m | $10.0m
EBITDA
- | -
EBIT
$-3.5m | -
Net Income
$-3.4m | $-80.0k
Free Cash Flow
$-4.0m
Growth (TTM | estimate)
Revenue
48.6% | 111.0%
EBITDA
- | -
EBIT
-2.7% | -
Net Income
24.8% | 97.7%
Free Cash Flow
-4.4%
Margin (TTM | estimate)
Gross
65.4%
EBITDA
- | -
EBIT
-73.5%
Net
-71.6% | -0.8%
Free Cash Flow
-84.2%
More
EPS
$0.0
FCF per Share
$0.0
Short interest
1.5%
Employees
7
Rev per Employee
$680.0k
Show more

Is Immuron Limited Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Financial data from Immuron Limited Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
4.74 4.74
49% 49%
100%
- Direct Costs 1.64 1.64
61% 61%
35%
3.10 3.10
43% 43%
65%
- Selling and Administrative Expenses 5.17 5.17
21% 21%
109%
- Research and Development Expense 2.34 2.34
33% 33%
49%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -3.49 -3.49
3% 3%
-74%
Net Profit -3.40 -3.40
25% 25%
-72%

In millions USD.

Don't miss a Thing! We will send you all news about Immuron Limited Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immuron Limited Sponsored ADR Stock News

Neutral
GlobeNewsWire
3 days ago
Sales Highlights (unaudited): Global • Q1 sales AUD$2.0 million up 34% on prior comparative period (pcp)       Australia • Q1 sales AUD$1.6 million up 52% on pcp       Canada • Q1 sales AUD$0.0 million down 92% on pcp       USA • Q1 sales AUD$0.4 million up 44% on pcp MELBOURNE, Australia, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and global...
Neutral
GlobeNewsWire
8 days ago
Key Points Immuron submits Investigational new drug (IND) application to FDA for clinical development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI) Previous clinical trial data on IMM-529 provides support for continued development of IMM-529 MELBOURNE, Australia, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), is plea...
Neutral
GlobeNewsWire
14 days ago
Highlights: US Tariffs: Immuron does not anticipate any material impact from the recently announced US tariffs on pharmaceutical products Travelan® Clinical Study: Topline results from the Travelan® clinical study conducted by Uniformed Services University are anticipated in October 2025 IMM-529 Regulatory Milestone: Immuron plans to submit an Investigational New Drug (IND) application to the U...
More Immuron Limited Sponsored ADR News

Company Profile

Immuron Ltd. engages in the research and development of oral immunotherapy, and product sales which focuses on bovine-colostrum with antibodies of choice for the treatment and prevention of a range of infectious and immune modulated diseases. It operates through the following segments: Research and Development, and HyperImmune Products.The Research and Development segment involves the R&D projects performed in Australia, Israel, and United States. The HyperImmune Products segment comprises of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994 and is headquartered in Carlton, Australia.

Head office Australia
CEO Mr. Lydeamore
Employees 7
Founded 1994
Website www.immuron.com.au

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today